These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22064454)

  • 1. Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies.
    Altintas I; Kok RJ; Schiffelers RM
    Eur J Pharm Sci; 2012 Mar; 45(4):399-407. PubMed ID: 22064454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting.
    Omidfar K; Shirvani Z
    DNA Cell Biol; 2012 Jun; 31(6):1015-26. PubMed ID: 22277093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the EGF receptor ectodomain in the context of cancer.
    Huang L; De Baetselier P; Beyaert R
    Expert Opin Ther Targets; 2009 Nov; 13(11):1347-61. PubMed ID: 19769546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of a human anti-epidermal growth factor receptor Fab antibody, EG-19-11, with subnanomolar affinity from naïve immunoglobulin repertoires using a hierarchical antibody library system.
    Hur BU; Yoon JB; Liu LK; Cha SH
    Immunol Lett; 2010 Nov; 134(1):55-61. PubMed ID: 20797408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
    Khalil MY; Grandis JR; Shin DM
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tumors with nanobodies for cancer imaging and therapy.
    Oliveira S; Heukers R; Sornkom J; Kok RJ; van Bergen En Henegouwen PM
    J Control Release; 2013 Dec; 172(3):607-17. PubMed ID: 24035975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments.
    Kataoka H
    J Dermatol Sci; 2009 Dec; 56(3):148-53. PubMed ID: 19896805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
    Lammerts van Bueren JJ; Bleeker WK; Bøgh HO; Houtkamp M; Schuurman J; van de Winkel JG; Parren PW
    Cancer Res; 2006 Aug; 66(15):7630-8. PubMed ID: 16885363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the EGFR in neoplasia--more questions than answers.
    Dicker AP; Rodeck U
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):899-902. PubMed ID: 14967449
    [No Abstract]   [Full Text] [Related]  

  • 13. Isolation of novel EGFR-specific VHH domains.
    Gottlin EB; Xiangrong Guan ; Pegram C; Cannedy A; Campa MJ; Patz EF
    J Biomol Screen; 2009 Jan; 14(1):77-85. PubMed ID: 19171923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobodies in therapeutic applications.
    Roovers RC; van Dongen GA; van Bergen en Henegouwen PM
    Curr Opin Mol Ther; 2007 Aug; 9(4):327-35. PubMed ID: 17694445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of ErbB4 antibodies for cancer therapy.
    Hollmén M; Elenius K
    Future Oncol; 2010 Jan; 6(1):37-53. PubMed ID: 20021208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
    Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M
    Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
    Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
    Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
    Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeting therapy directed against growth factor receptor].
    Ueda M; Abe O; Shimizu N
    Tanpakushitsu Kakusan Koso; 1991 May; 36(7):1436-42. PubMed ID: 1871365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.